1. Met and its ligand HGF are associated with clinical outcome in breast cancer
   Cynthia Veenstra et al, 2016, Oncotarget CrossRef
2. Macrophage HIF‐2α regulates tumor‐suppressive Spint1 in the tumor microenvironment
   Rosa M. Susen et al, 2019, Molecular Carcinogenesis CrossRef
3. Hepatocyte growth factor is a prognostic marker in patients with colorectal cancer: a meta-analysis
   Chao-yuan Huang et al, 2017, Oncotarget CrossRef
4. Targeting the effect of sofosbuvir on selective oncogenes expression level of hepatocellular carcinoma Ras/Raf/MEK/ERK pathway in Huh7 cell line
   Muhammad Atif et al, 2022, Saudi Journal of Biological Sciences CrossRef
5. Comprehensive Analysis of the Expression and Prognostic Value of SPINT1/2 in Breast Carcinoma
   Qiulin Wu et al, 2021, Frontiers in Endocrinology CrossRef
6. TargetingHGFwith Antibodies as an Anti‐Cancer Therapeutic Strategy
   Dinuka M. De Silva et al, 2018, Extracellular Targeting of Cell Signaling in Cancer CrossRef
7. Hepatocyte growth factor pathway expression in breast cancer by race and subtype
   Gieira S. Jones et al, 2021, Breast Cancer Research CrossRef
8. Bioinformatics analysis identifies potential chemoresistance‑associated genes across multiple types of cancer
   Jingsheng Yuan et al, 2019, Oncology Letters CrossRef
9. Hepatocyte growth factor/MET in cancer progression and biomarker discovery
   Kunio Matsumoto et al, 2017, Cancer Science CrossRef
10. MiRNA-200a expression is inverse correlation with hepatocyte growth factor expression in stromal fibroblasts and its high expression predicts a good prognosis in patients with non-small cell lung cancer
    Yongbing Chen et al, 2016, Oncotarget CrossRef
11. High hepatocyte growth factor expression in primary tumor predicts better overall survival in male breast cancer
    Si-Qi Qiu et al, 2020, Breast Cancer Research CrossRef